142 related articles for article (PubMed ID: 21275049)
1. Synthesis and evaluation of potent ene-yne inhibitors of type II dehydroquinases as tuberculosis drug leads.
Tran AT; Cergol KM; West NP; Randall EJ; Britton WJ; Bokhari SA; Ibrahim M; Lapthorn AJ; Payne RJ
ChemMedChem; 2011 Feb; 6(2):262-5. PubMed ID: 21275049
[No Abstract] [Full Text] [Related]
2. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
[TBL] [Abstract][Full Text] [Related]
3. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
[TBL] [Abstract][Full Text] [Related]
4. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
Tran AT; West NP; Britton WJ; Payne RJ
ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
[TBL] [Abstract][Full Text] [Related]
5. (1R,4S,5R)-3-Fluoro-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid: the fluoro analogue of the enolate intermediate in the reaction catalyzed by type II dehydroquinases.
Frederickson M; Roszak AW; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2004 Jun; 2(11):1592-6. PubMed ID: 15162210
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis.
Banerjee DR; Biswas R; Das AK; Basak A
Eur J Med Chem; 2015 Jul; 100():223-34. PubMed ID: 26092447
[TBL] [Abstract][Full Text] [Related]
7. Determination of the bound conformation of a competitive nanomolar inhibitor of mycobacterium tuberculosis type II dehydroquinase by NMR spectroscopy.
Prazeres VF; Sánchez-Sixto C; Castedo L; Canales A; Cañada FJ; Jiménez-Barbero J; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2006 Sep; 1(9):990-6. PubMed ID: 16952136
[TBL] [Abstract][Full Text] [Related]
8. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
[TBL] [Abstract][Full Text] [Related]
9. A new family of inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
Gasse C; Huteau V; Douguet D; Munier-Lehmann H; Pochet S
Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1057-61. PubMed ID: 18058536
[No Abstract] [Full Text] [Related]
10. Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach.
Schmidt MF; Korb O; Howard NI; Dias MV; Blundell TL; Abell C
ChemMedChem; 2013 Jan; 8(1):54-8. PubMed ID: 23169689
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
Vanheusden V; Munier-Lehmann H; Pochet S; Herdewijn P; Van Calenbergh S
Bioorg Med Chem Lett; 2002 Oct; 12(19):2695-8. PubMed ID: 12217356
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and structural studies on potent biaryl inhibitors of type II dehydroquinases.
Payne RJ; Riboldi-Tunnicliffe A; Kerbarh O; Abell AD; Lapthorn AJ; Abell C
ChemMedChem; 2007 Jul; 2(7):1010-3. PubMed ID: 17487901
[No Abstract] [Full Text] [Related]
13. Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Menendez C; Chollet A; Rodriguez F; Inard C; Pasca MR; Lherbet C; Baltas M
Eur J Med Chem; 2012 Jun; 52():275-83. PubMed ID: 22483635
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
[TBL] [Abstract][Full Text] [Related]
15. Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors.
Munier-Lehmann H; Pochet S; Dugue L; Dutruel O; Labesse G; Douget D
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):801-4. PubMed ID: 14565282
[No Abstract] [Full Text] [Related]
16. Exploring acyclic nucleoside analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
Familiar O; Munier-Lehmann H; Negri A; Gago F; Douguet D; Rigouts L; Hernández AI; Camarasa MJ; Pérez-Pérez MJ
ChemMedChem; 2008 Jul; 3(7):1083-93. PubMed ID: 18418833
[TBL] [Abstract][Full Text] [Related]
17. 2-substituted-3-dehydroquinic acids as potent competitive inhibitors of type II dehydroquinase.
Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2009 Dec; 4(12):1980-4. PubMed ID: 19856378
[No Abstract] [Full Text] [Related]
18. Structure-and-mechanism-based design and discovery of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors.
Yao Y; Li ZS
Curr Top Med Chem; 2014; 14(1):51-63. PubMed ID: 24236726
[TBL] [Abstract][Full Text] [Related]
19. Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.
Odell LR; Nilsson MT; Gising J; Lagerlund O; Muthas D; Nordqvist A; Karlén A; Larhed M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4790-3. PubMed ID: 19560924
[TBL] [Abstract][Full Text] [Related]
20. A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
Yang Y; Gao P; Liu Y; Ji X; Gan M; Guan Y; Hao X; Li Z; Xiao C
Bioorg Med Chem Lett; 2011 Jul; 21(13):3943-6. PubMed ID: 21641210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
